<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04353310</url>
  </required_header>
  <id_info>
    <org_study_id>Loma Linda University</org_study_id>
    <secondary_id>145101</secondary_id>
    <nct_id>NCT04353310</nct_id>
  </id_info>
  <brief_title>Evaluating Effects of Curcumin in Moderate to Severe Asthmatics</brief_title>
  <official_title>Evaluating the Effects of Curcumin in Moderate to Severe Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this investigator-initiated study is to evaluate the effects of oral curcumin
      supplementation versus placebo in adult patients with moderate to severe asthma. Curcumin, a
      derivative of turmeric, has been shown in animal models to inhibit the secretion of
      pro-inflammatory cytokines and decrease airway constriction and hyperreactivity with only a
      few observational studies available in humans with discordant results.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Asthma Control</measure>
    <time_frame>3 months</time_frame>
    <description>defined by the Asthma Control Test, which has a 5-point scale (for symptoms and activities: 1=all the time to 5= not at all; for asthma control rating: 1=not controlled at all to 5=completely controlled)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Severe Asthma Exacerbations in 3 Months</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Days Missed From School or Work in 3 Months</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometry</measure>
    <time_frame>3 months</time_frame>
    <description>FEV1/FVC ratio, FEV1: forced expiratory volume in one second, FVC: forced vital capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exhaled nitric oxide</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total IgE</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma eosinophil count</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>Curcumin 1500mg PO BID</description>
    <arm_group_label>Curcumin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>identical in appearance to curcumin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of signed and dated informed consent form

          2. Stated willingness to comply with all study procedures and availability for the
             duration of the study

          3. Male or female, aged 18 and older

          4. Physician diagnosed moderate to severe asthma: (GINA 2018)

             a. Stable asthma that requires ICS/LABA and/or an additional controller agent (i.e.
             LTRA, LAMA)

          5. Ability to take oral medication and be willing to adhere to the regimen

          6. Ability to speak and read English

          7. If female and sexually active, should use effective forms of birth control

        Exclusion Criteria:

          1. Current use of turmeric (curcumin) or use within the last 7 days

          2. Current use of biologic therapy/ immunotherapy/ or bronchothermoplasty

          3. Pregnancy or lactation

          4. Known allergic reactions to components of turmeric (curcumin)

          5. Current use of anticoagulants, and history of coagulopathy or liver disease

          6. INR greater than 2.0, PTT greater than 45.0 seconds
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michele Quan, MD</last_name>
    <phone>9095584000</phone>
    <phone_ext>82962</phone_ext>
    <email>miquan@llu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laren Tan, MD</last_name>
    <phone>9095584000</phone>
    <phone_ext>82962</phone_ext>
    <email>latan@llu.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, de Jongste JC, Kerstjens HA, Lazarus SC, Levy ML, O'Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stoloff SW, Sullivan SD, Szefler SJ, Thomas MD, Wenzel SE; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009 Jul 1;180(1):59-99. doi: 10.1164/rccm.200801-060ST.</citation>
    <PMID>19535666</PMID>
  </reference>
  <reference>
    <citation>Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, de Jongste JC, Kerstjens HA, Lazarus SC, Levy ML, O'Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stoloff SW, Szefler SJ, Sullivan SD, Thomas MD, Wenzel SE, Reddel HK. A new perspective on concepts of asthma severity and control. Eur Respir J. 2008 Sep;32(3):545-54. doi: 10.1183/09031936.00155307.</citation>
    <PMID>18757695</PMID>
  </reference>
  <reference>
    <citation>Aggarwal BB, Surh YJ, Shishodia S (Eds.). Mol. Targets Ther. Uses Curcumin Health Dis, Springer, US. 2007; 1-75.</citation>
  </reference>
  <reference>
    <citation>Baldwin AS Jr. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest. 2001 Jan;107(1):3-6. Review.</citation>
    <PMID>11134170</PMID>
  </reference>
  <reference>
    <citation>Oh SW, Cha JY, Jung JE, Chang BC, Kwon HJ, Lee BR, Kim DY. Curcumin attenuates allergic airway inflammation and hyper-responsiveness in mice through NF-ÎºB inhibition. J Ethnopharmacol. 2011 Jul 14;136(3):414-21. doi: 10.1016/j.jep.2010.07.026. Epub 2010 Jul 17.</citation>
    <PMID>20643202</PMID>
  </reference>
  <reference>
    <citation>Liu L, Shang Y, Li M, Han X, Wang J, Wang J. Curcumin ameliorates asthmatic airway inflammation by activating nuclear factor-E2-related factor 2/haem oxygenase (HO)-1 signalling pathway. Clin Exp Pharmacol Physiol. 2015 May;42(5):520-9. doi: 10.1111/1440-1681.12384.</citation>
    <PMID>25739561</PMID>
  </reference>
  <reference>
    <citation>Wong CK, Li ML, Wang CB, Ip WK, Tian YP, Lam CW. House dust mite allergen Der p 1 elevates the release of inflammatory cytokines and expression of adhesion molecules in co-culture of human eosinophils and bronchial epithelial cells. Int Immunol. 2006 Aug;18(8):1327-35. Epub 2006 Jun 23.</citation>
    <PMID>16798840</PMID>
  </reference>
  <reference>
    <citation>Wuyts WA, Vanaudenaerde BM, Dupont LJ, Demedts MG, Verleden GM. Involvement of p38 MAPK, JNK, p42/p44 ERK and NF-kappaB in IL-1beta-induced chemokine release in human airway smooth muscle cells. Respir Med. 2003 Jul;97(7):811-7.</citation>
    <PMID>12854631</PMID>
  </reference>
  <reference>
    <citation>Kobayashi T, Hashimoto S, Horie T. Curcumin inhibition of Dermatophagoides farinea-induced interleukin-5 (IL-5) and granulocyte macrophage-colony stimulating factor (GM-CSF) production by lymphocytes from bronchial asthmatics. Biochem Pharmacol. 1997 Oct 1;54(7):819-24.</citation>
    <PMID>9353136</PMID>
  </reference>
  <reference>
    <citation>Ram A, Das M, Ghosh B. Curcumin attenuates allergen-induced airway hyperresponsiveness in sensitized guinea pigs. Biol Pharm Bull. 2003 Jul;26(7):1021-4.</citation>
    <PMID>12843631</PMID>
  </reference>
  <reference>
    <citation>Kim DH, Phillips JF, Lockey RF. Oral curcumin supplementation in patients with atopic asthma. Allergy Rhinol (Providence). 2011 Apr;2(2):e51-3. doi: 10.2500/ar.2011.2.0016.</citation>
    <PMID>22852117</PMID>
  </reference>
  <reference>
    <citation>Abidi A, Gupta S, Agarwal M, Bhalla HL, Saluja M. Evaluation of Efficacy of Curcumin as an Add-on therapy in Patients of Bronchial Asthma. J Clin Diagn Res. 2014 Aug;8(8):HC19-24. doi: 10.7860/JCDR/2014/9273.4705. Epub 2014 Aug 20.</citation>
    <PMID>25302215</PMID>
  </reference>
  <reference>
    <citation>Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013 Jan;15(1):195-218. doi: 10.1208/s12248-012-9432-8. Epub 2012 Nov 10. Review.</citation>
    <PMID>23143785</PMID>
  </reference>
  <reference>
    <citation>Basnet P, Skalko-Basnet N. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules. 2011 Jun 3;16(6):4567-98. doi: 10.3390/molecules16064567. Review.</citation>
    <PMID>21642934</PMID>
  </reference>
  <reference>
    <citation>Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001 Jul-Aug;21(4B):2895-900.</citation>
    <PMID>11712783</PMID>
  </reference>
  <reference>
    <citation>Lao CD, Ruffin MT 4th, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006 Mar 17;6:10.</citation>
    <PMID>16545122</PMID>
  </reference>
  <reference>
    <citation>Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol. 2009 Oct;124(4):719-23.e1. doi: 10.1016/j.jaci.2009.06.053. Epub 2009 Sep 19.</citation>
    <PMID>19767070</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 13, 2019</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2020</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>Laren Tan, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>curcumin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

